Simple Summary Patients with advanced melanoma are often treated with v-raf murine
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …

Transposon mutagenesis has been used to model many types of human cancer in mice,
leading to the discovery of novel cancer genes and insights into the mechanism of …

The nongenetic mechanisms required to control tumor phenotypic plasticity and shape drug‐
resistance remain unclear. We show here that the Aryl hydrocarbon Receptor (AhR) …

Src plays a crucial role in many signaling pathways and contributes to a variety of cancers.
Therefore, Src has long been considered an attractive drug target in oncology. However, the …

Patients with malignant melanoma have a 5-year survival rate of only 15–20% once the
tumor has metastasized to distant tissues. While MAP kinase pathway inhibitors (MAPKi) are …

Rare gain-of-function mutations in RAC1 drive drug resistance to targeted BRAF inhibition in
cutaneous melanoma. Here, we show that wildtype RAC1 is a critical driver of growth and …

Background The mechanism of action for most cancer drugs is not clear. Large-scale
pharmacogenomic cancer cell line datasets offer a rich resource to obtain this knowledge …

The family of p21-activated kinases (PAKs) are oncogenic proteins that regulate critical
cellular functions. PAKs play central signaling roles in the integrin/CDC42/Rho, ERK/MAPK …

Abstract BRAF V600-and MEK1/2-targeting therapies rarely produce durable response in
melanoma patients. We investigated five BRAF V600E melanoma cell lines derived from …

The evolution of therapeutic resistance is a major obstacle to the success of targeted
oncology drugs. While both inter-and intratumoral heterogeneity limit our ability to detect …